Skip to main content
Erschienen in: Breast Cancer 4/2016

17.05.2015 | Original Article

Microinvasive breast cancer: pathological parameters, cancer subtypes distribution, and correlation with axillary lymph nodes invasion. Results of a large single-institution series

verfasst von: Lorenzo Orzalesi, Donato Casella, Valentina Criscenti, Ulpiana Gjondedaj, Simonetta Bianchi, Vania Vezzosi, Jacopo Nori, Lorenzo Cecconi, Icro Meattini, Lorenzo Livi, Marco Bernini

Erschienen in: Breast Cancer | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Microinvasive breast cancer is a rare entity in which an invasive component not exceeding 1 mm is found, mostly in a ductal carcinoma in situ setting. Its diagnosis can be difficult and must rely upon immunohistochemistry markers. Many studies have analyzed pathological characteristics of this cancer to delineate its biological profile and possibly identify risk factors of axillary lymph nodes infiltration, which might be present and therefore clinically relevant. Starting from a relative large number of cases we aimed to analyze pathological data, cancer subtypes distribution, and their correlation to nodal metastasis, comparing our results to the existing recent literature.

Methods

All cases of microinvasive breast cancer were retrieved from institutional database from 1992 to 2014. Pathological parameters were analyzed for entire cohort. Moreover, cases submitted to standardized sentinel node biopsy in a restricted period, 2000–2014, were selected to correlate pathology and cancer subtype to axillary lymph nodes status.

Results

174 cases (1.4 % of operated breast cancers) were evaluated in the larger period, 1992–2014. Neither specific pathological parameters were expressed nor a peculiar cancer subtype was represented. 126 cases were selected for axillary staging analysis. Eighteen cases (14.3 %) had lymph nodes metastasis, 10 ITCs (7.9 %), 3 micrometastases (2.4 %), and 5 macrometastases (4 %). An associated intraductal component of carcinoma over 20 mm in maximum dimension resulted significant at multivariate analysis, but only if including ITCs, while this risk factor was not reproduced for micro- and macrometastases only.

Conclusions

Microinvasive breast cancer does not seem to have specific pathological and biological traits. An associated intraductal component of carcinoma >20 mm in size is a specific risk factor for ITCs nodal metastasis. Its clinical significance is anyway limited and therefore sentinel node biopsy should be performed case by case and not routinely.
Literatur
1.
Zurück zum Zitat Lagios MD, Westdahl PR, Margolin FR, Rose MR. Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer. 1982;50(7):1309–14.CrossRefPubMed Lagios MD, Westdahl PR, Margolin FR, Rose MR. Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer. 1982;50(7):1309–14.CrossRefPubMed
2.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. American Joint Committee on Cancer. AJCC cancer staging manual, vol. VIII. 7th ed. New York: Springer; 2010. p. 345–77. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. American Joint Committee on Cancer. AJCC cancer staging manual, vol. VIII. 7th ed. New York: Springer; 2010. p. 345–77.
3.
Zurück zum Zitat Pinder SE, Ellis IO, Schnitt SJ, Tan PH, Rutgers E, Morrow M. Microinvasive carcinoma. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van de vijvair MJ, editors. WHO classification of tumors of the breast. Lyon: IARC Press; 2012. p. 96–7. Pinder SE, Ellis IO, Schnitt SJ, Tan PH, Rutgers E, Morrow M. Microinvasive carcinoma. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van de vijvair MJ, editors. WHO classification of tumors of the breast. Lyon: IARC Press; 2012. p. 96–7.
4.
Zurück zum Zitat Nemoto T, Castillo N, Tsukada Y, Koul A, Eckhert KH Jr, Bauer RL. Lobular carcinoma in situ with microinvasion. J Surg Oncol. 1998;67:41–6.CrossRefPubMed Nemoto T, Castillo N, Tsukada Y, Koul A, Eckhert KH Jr, Bauer RL. Lobular carcinoma in situ with microinvasion. J Surg Oncol. 1998;67:41–6.CrossRefPubMed
5.
Zurück zum Zitat Bianchi S, Vezzosi V. Microinvasive carcinoma of the breast. Pathol Oncol Res. 2008;14:105–11.CrossRefPubMed Bianchi S, Vezzosi V. Microinvasive carcinoma of the breast. Pathol Oncol Res. 2008;14:105–11.CrossRefPubMed
6.
Zurück zum Zitat Schnitt SJ. Microinvasive carcinoma of the breast: a diagnosis in search of a definition. Adv Anat Pathol. 1998;5:367–72.PubMed Schnitt SJ. Microinvasive carcinoma of the breast: a diagnosis in search of a definition. Adv Anat Pathol. 1998;5:367–72.PubMed
7.
Zurück zum Zitat Olivotto I, Levine M. Steering committee on clinical practice guidelines for the care and treatment of breast cancer. Clinical practice guidelines for the care and treatment of breast cancer: the management of ductal carcinoma in situ (summary of the 2001 update). CMAJ. 2001;165:912–3.PubMedPubMedCentral Olivotto I, Levine M. Steering committee on clinical practice guidelines for the care and treatment of breast cancer. Clinical practice guidelines for the care and treatment of breast cancer: the management of ductal carcinoma in situ (summary of the 2001 update). CMAJ. 2001;165:912–3.PubMedPubMedCentral
8.
Zurück zum Zitat Yaziji H, Gown AM, Sneige N. Detection of stromal invasion in breast cancer: the myoepithelial markers. Adv Anat Pathol. 2000;7(2):100–9.CrossRefPubMed Yaziji H, Gown AM, Sneige N. Detection of stromal invasion in breast cancer: the myoepithelial markers. Adv Anat Pathol. 2000;7(2):100–9.CrossRefPubMed
9.
Zurück zum Zitat Damiani S, Ludvikova M, Tomasic G, Bianchi S, Gown AM, Eusebi V. Myoepithelial cells and basal lamina in poorly differentiated in situ duct carcinoma of the breast: an immunocytochemical study. Virchows Arch. 1999;434:227–34.CrossRefPubMed Damiani S, Ludvikova M, Tomasic G, Bianchi S, Gown AM, Eusebi V. Myoepithelial cells and basal lamina in poorly differentiated in situ duct carcinoma of the breast: an immunocytochemical study. Virchows Arch. 1999;434:227–34.CrossRefPubMed
10.
Zurück zum Zitat Werling RW, Hwang H, Yaziji H, Gown AM. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol. 2003;27(1):82–90.CrossRefPubMed Werling RW, Hwang H, Yaziji H, Gown AM. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol. 2003;27(1):82–90.CrossRefPubMed
11.
Zurück zum Zitat Yu KD, Wu LM, Liu GY, Wu J, Di GH, Shen ZZ, et al. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. Ann Surg Oncol. 2011;18(5):1342–8.CrossRefPubMed Yu KD, Wu LM, Liu GY, Wu J, Di GH, Shen ZZ, et al. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. Ann Surg Oncol. 2011;18(5):1342–8.CrossRefPubMed
12.
Zurück zum Zitat Margalit DN, Sreedhara M, Chen YH, Catalano PJ, Nguyen PL, Golshan M, et al. Microinvasive breast cancer: ER, PR and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy. Ann Surg Oncol. 2013;20(3):811–8.CrossRefPubMed Margalit DN, Sreedhara M, Chen YH, Catalano PJ, Nguyen PL, Golshan M, et al. Microinvasive breast cancer: ER, PR and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy. Ann Surg Oncol. 2013;20(3):811–8.CrossRefPubMed
13.
Zurück zum Zitat Shatat L, Gloyeske N, Madan R, O’Neil M, Tawfik O, Fan F. Microinvasive breast carcinoma carries an excellent prognosis regardless of the tumor characteristics. Hum Pathol. 2013;44:2684–9.CrossRefPubMed Shatat L, Gloyeske N, Madan R, O’Neil M, Tawfik O, Fan F. Microinvasive breast carcinoma carries an excellent prognosis regardless of the tumor characteristics. Hum Pathol. 2013;44:2684–9.CrossRefPubMed
14.
Zurück zum Zitat Gojon H, Fawunmi D, Valachis A. Sentinel lymph node biopsy in patients with microinvasive breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2014;40:5–11.CrossRefPubMed Gojon H, Fawunmi D, Valachis A. Sentinel lymph node biopsy in patients with microinvasive breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2014;40:5–11.CrossRefPubMed
15.
Zurück zum Zitat Burkhardt L, Grob TJ, Hermann I, Burandt E, Choschzick M, Jänicke F, et al. Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2010;123(3):757–65.CrossRefPubMed Burkhardt L, Grob TJ, Hermann I, Burandt E, Choschzick M, Jänicke F, et al. Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2010;123(3):757–65.CrossRefPubMed
16.
Zurück zum Zitat Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Stat Med. 2002;21:2409–19.CrossRefPubMed Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Stat Med. 2002;21:2409–19.CrossRefPubMed
17.
Zurück zum Zitat Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J. Danish Breast Cancer Cooperative Group. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26(9):1419–26.CrossRefPubMed Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J. Danish Breast Cancer Cooperative Group. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26(9):1419–26.CrossRefPubMed
18.
Zurück zum Zitat Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26(14):2373–8.CrossRefPubMed Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26(14):2373–8.CrossRefPubMed
19.
Zurück zum Zitat Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5(1):63–9.CrossRefPubMed Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5(1):63–9.CrossRefPubMed
21.
Zurück zum Zitat Fortunato L, Santoni M, Drago S, Gucciardo G, Farina M, Cesarini C, et al. Rome Breast Cancer Study Group. Sentinel lymph node biopsy in women with pT1a or “microinvasive” breast cancer. Breast. 2008;17:395–400.CrossRefPubMed Fortunato L, Santoni M, Drago S, Gucciardo G, Farina M, Cesarini C, et al. Rome Breast Cancer Study Group. Sentinel lymph node biopsy in women with pT1a or “microinvasive” breast cancer. Breast. 2008;17:395–400.CrossRefPubMed
22.
Zurück zum Zitat Adamovich TL, Simmons RM. Ductal carcinoma in situ with microinvasion. Am J Surg. 2003;186:112–6.CrossRefPubMed Adamovich TL, Simmons RM. Ductal carcinoma in situ with microinvasion. Am J Surg. 2003;186:112–6.CrossRefPubMed
25.
Zurück zum Zitat Kapoor NS, Shamonki J, Sim MS, Chung CT, Giuliano AE. Impact of multifocality and lymph node metastasis on the prognosis and management of microinvasive breast cancer. Ann Surg Oncol. 2013;20(8):2576–81. doi:10.1245/s10434-013-2924-7.CrossRefPubMed Kapoor NS, Shamonki J, Sim MS, Chung CT, Giuliano AE. Impact of multifocality and lymph node metastasis on the prognosis and management of microinvasive breast cancer. Ann Surg Oncol. 2013;20(8):2576–81. doi:10.​1245/​s10434-013-2924-7.CrossRefPubMed
26.
Zurück zum Zitat Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B. Senn HJ; Panel members. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736–47. doi:10.1093/annonc/mdr304.CrossRefPubMedPubMedCentral Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B. Senn HJ; Panel members. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736–47. doi:10.​1093/​annonc/​mdr304.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297–305. doi:10.1016/S1470-2045(13)70035-4.CrossRefPubMedPubMedCentral Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297–305. doi:10.​1016/​S1470-2045(13)70035-4.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426–32. doi:10.1097/SLA.0b013e3181f08f32.PubMed Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426–32. doi:10.​1097/​SLA.​0b013e3181f08f32​.PubMed
Metadaten
Titel
Microinvasive breast cancer: pathological parameters, cancer subtypes distribution, and correlation with axillary lymph nodes invasion. Results of a large single-institution series
verfasst von
Lorenzo Orzalesi
Donato Casella
Valentina Criscenti
Ulpiana Gjondedaj
Simonetta Bianchi
Vania Vezzosi
Jacopo Nori
Lorenzo Cecconi
Icro Meattini
Lorenzo Livi
Marco Bernini
Publikationsdatum
17.05.2015
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 4/2016
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-015-0616-9

Weitere Artikel der Ausgabe 4/2016

Breast Cancer 4/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.